Yuhan Corp showed improved performance in Q1 compared to the previous year. A large amount of revenue from contract development and manufacturing (CDMO) royalties flowed in from its subsidiary Ad Pharma.

Yuhan Corp announced on the 26th that operating profit based on its consolidated financial statements in Q1 was KRW 22.6 billion, which is a 3.7-fold increase from the KRW 6.1 billion in the same period of the previous year. Sales were KRW 443 billion, up 7.8% from the previous year.

Its royalty revenue has increased significantly from KRW 1.5 billion in Q1 last year to KRW 7.2 billion.

Yuhan Corp has signed licensing-out deals for new drug technologies from 5 glob